How studying hematological malignancies subtypes may inform epidemiologic and clinical research

Personalized breast cancer therapy based on viral functional assays to score pathway activity Harald Wodrich, University of Bordeaux State-of-the-art mass sequencing technology has paved the road

Clinicaland biological samples : opportunities and challenges for translational research

En point d'orgue du Scientific BRIO Day, David Cameron, spécialiste reconnu en Oncologie, Professeur  à l'Université d'Edimbourg, anime un débat sur la question des opportinités et bonnes pratiques

Epidemiology and public health Lawsuits against the tobacco industry, if successful, have the potential to compensate victims of smoking and to diminish the capacity of the tobacco industry to

Clinical and biological samples : opportunities and challenges for translational research A challenge in oncology is to better define the tumor of the patient to study the pathology and of course

About BRIO Siric challenges and actions   BRIO’s strategic objective is to strengthen Bordeaux’s leadership in Cancer Research through the creation of a dynamic cancer research community, the

Epidemiology and public health   The principal aim of this thesis will describe the care pathway of diffuse large B cell lymphoma (DBCL) and follicular lymphoma (FL) in the general population and

About BRIO Siric challenges and actions   The success of BRIO’s approach and the realization of its potential impact on the translational research community in Bordeaux rely both on the efficient

Clinical and biological samples : opportunities and challenges for translational research   The first purpose of this talk is to provide ton non clinical researchers some main technical, ethical

Clinical biology session The main sarcoma databases are the Conticabase (https://conticabase.sarcomabcb.org) and the ConticaGist (https://conticagist.sarcomabcb.org) with 18000 patients and which

Epidemiology and public health In oncology, the international WHO and RECIST criteria have allowed the standardization of tumor response evaluation in order to identify the time of disease